Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

Discovery of First-in-Class Precision Antibody Drug Conjugates Targeting Mutant Calreticulin For the Treatment of Myeloproliferative Neoplasms

Wednesday, June 18, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the discovery of a novel class of precision antibody drug conjugates aimed at treating myeloproliferative neoplasms by targeting mutant calreticulin. This innovative approach could lead to significant advancements in patient care and treatment efficacy. The research team includes a diverse group of scientists and experts in the field.
Price reaction · baseline $0.9275 (2025-06-17 close) · hit pre-market · clean, no other PRLD news in the window
day 0 close
-7.2%
day 1 · peak
-7.2%
day 3
-5.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of first-in-class precision antibody drug conjugates.
  • Targeting mutant calreticulin shows promise for treatment.
  • Potential to improve outcomes for patients with myeloproliferative neoplasms.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Norman Fultang, Ashley Schwab, Sharayu Chandratre, Ian Johnson, Jake Karwoski, Neha Bhagwat, Arpita Mondal, Min Wang, Yue Zou, Andrew Buesking, Max Foroutan, Chun Chen, Corey Basch, Ryan Holmes, Sang Hyun Lee, Diane Heiser, Andrew Combs, Peggy Scherle

Frequently Asked Questions

What are precision antibody drug conjugates?

Precision antibody drug conjugates are targeted therapies designed to deliver drugs directly to cancer cells.

What condition do these drug conjugates target?

They specifically target myeloproliferative neoplasms associated with mutant calreticulin.

Who are the researchers involved in this discovery?

The research team includes Norman Fultang, Ashley Schwab, and several other experts.

What is the significance of targeting mutant calreticulin?

Targeting mutant calreticulin may enhance treatment effectiveness for patients with specific cancer types.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare myeloproliferative neoplasms calreticulin antibody drug conjugates precision medicine
Last updated: Jun 18, 2025

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →